Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma

Frontiers of Radiation Therapy and Oncology

Volumn 33, Issue , 1999, Pages 364-368

  Grabenbauer, Gerhard G ^a   Buchfelder, Michael ^a   Schrell, Ulrich ^a   Fahlbusch, Rudolf ^a   Sauer, Rolf ^a   Staab, Hans Jürgen ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b SmithKline Beecham   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TOPOTECAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; RADIOTHERAPY, CONFORMAL; TOPOTECAN;

EID: 0032623252     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000061220     Document Type: Article

References (9)

1. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Steward CF: Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996;37:195-202.
2. Creemers GJ, Gerrits CJ, Schellens JH, Planting AS, van den Burg ME, van Beurden VM, de BoerDennert M, Harteveld M, Loos W, Hudson I, Stoter G, Verweij J: Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996;14:2540-2545.
3. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L: Chemotherapy response criteria in malignant glioma. Neurology 1997;48:1336-1340.
4. Herben VM, ten Bokkel-Huinink WW, Schot ME, Hudson I, Beijnen JH: Continuous infusion of lowdose topotecan: Pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. Anticancer Drugs 1998;9:411-418.
5. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK: Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996;88:734-741.
6. Kim JH, Kim HS, Kolozvary A, Khil MS: Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase 1. Int J Radiat Oncol Biol Phys 1992;22:515-518.
7. Lamond JP, Mehta MP, Boothman DA: The potential of topoisomerase 1 inhibitors in the treatment of CNS malignancies: Report of a synergistic effect between topotecan and radiation. J Neurooncol 1996;30:1-6.
8. Macdonald D, Cairncross G, Steward D, Forsyth P, Sawka C, Wainman N, Eisenhauer E: Phase II study of topotecan in patients with recurrent malignant glioma. Ann Oncol 1996;7:205-207.
9. Sauer R, Heuser A: Topoisomerase-1-Inhibitor mit potentiell strahlensensibilisierender Wirkung. Strahlenther Onkol 1997;173:125-130.